MLLT3 and cancer: Some of the most prevalent included known pediatric cancer fusions RUNX1::RUNX1T1 (15% AML participants), KMT2A::MLLT3/MLLT10 (12% AML), TCF3::PBX1 (4.4% ALL), and ETV6::RUNX1 (2.4% ALL).